PART II / OGM - Global Adoption & U.S. Acceptance:
Post# of 61
(Total Views: 55)
Posted On: 05/07/2025 8:14:41 PM
PART II / OGM - Global Adoption & U.S. Acceptance:
If foreign biotech companies begin using OGM to develop superior therapies, U.S. pharmaceutical firms may be forced to adopt it to stay competitive.
If patients and hospitals demand better diagnostic accuracy, especially in conditions where OGM outperforms traditional methods, the FDA will face increasing pressure to approve it.
As BNGO’s stock rises and global markets recognize OGM’s potential, institutional investors will push for broader U.S. acceptance to avoid falling behind.
China has approved OGM for reproductive health applications, proving its clinical viability. As more Chinese hospitals integrate OGM into diagnostics, it sets a precedent the FDA cannot ignore.
European labs are actively studying and incorporating OGM, with France publishing multiple peer-reviewed studies validating its use in hematologic cancers.
The longer U.S. regulators and industry leaders delay, the more likely they are to lose their foothold in a rapidly advancing global genomics landscape.
If foreign biotech companies begin using OGM to develop superior therapies, U.S. pharmaceutical firms may be forced to adopt it to stay competitive.
If patients and hospitals demand better diagnostic accuracy, especially in conditions where OGM outperforms traditional methods, the FDA will face increasing pressure to approve it.
As BNGO’s stock rises and global markets recognize OGM’s potential, institutional investors will push for broader U.S. acceptance to avoid falling behind.
China has approved OGM for reproductive health applications, proving its clinical viability. As more Chinese hospitals integrate OGM into diagnostics, it sets a precedent the FDA cannot ignore.
European labs are actively studying and incorporating OGM, with France publishing multiple peer-reviewed studies validating its use in hematologic cancers.
The longer U.S. regulators and industry leaders delay, the more likely they are to lose their foothold in a rapidly advancing global genomics landscape.
(0)
(0)